Osteoporosis associated with neuroleptic treatment. A case report.
A 28-year-old woman developed osteoporosis following seven years of neuroleptic use. She presented with amenorrhea and profuse galactorrhea of four years' duration. Dual photon absorptionometry demonstrated reduced bone mineral density in the femur and spine. Serum calcium, phosphorus and alkaline phosphatase were normal. The patient was started on bromocriptine, and her bone density, serum prolactin, dehydroepiandrosterone sulfate, and free and total testosterone improved. No deterioration in her psychiatric condition occurred.
Kartaginer
J
J
Department of Obstetrics and Gynecology, Hutzel Hospital, Detroit, Michigan.
Ataya
K
K
Mercado
A
A
Abbasi
A
A
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced / Q000188:drug therapy; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D005687:Galactorrhea / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced / Q000188:drug therapy; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy
D014150:Antipsychotic Agents; D001971:Bromocriptine